HealthcareServices

Global Huntington’s Disease Market 2026–2030: Forecast Insights for Business Planning

February 25, 2026February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the huntington’s disease market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Huntington’s Disease Market expected to reach by 2030?

The Huntington’s disease market has expanded significantly in recent years. This market is projected to grow from $0.55 billion in 2025 to $0.64 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.9%. Historically, the market’s growth can be attributed to factors such as the identification of the htt gene mutation, the limited availability of curative treatments, increasing awareness of rare neurodegenerative diseases, a reliance on symptomatic therapies, and the rise in diagnoses through genetic testing.

The market size for Huntington’s disease is projected to experience substantial growth in the upcoming years. It is anticipated to reach a valuation of $1.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.5%. This projected expansion during the forecast period can be attributed to advancements in gene therapy and RNA-based treatments, increasing investment in rare disease research, a broadening clinical pipeline for disease-modifying therapies, a growing focus on early intervention strategies, and enhanced support from patient advocacy organizations. Key trends anticipated in the forecast period include a heightened emphasis on disease-modifying and gene silencing therapies, a wider uptake of genetic testing for early and accurate diagnosis, a rising focus on multidisciplinary symptom management approaches, the expansion of clinical trials addressing neurodegenerative disorders, and the growth of patient-centric care models and home-based management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22008&type=smp

What Drivers Are Driving Adoption Within The Huntington’s Disease Market?

The increasing occurrence of neurological disorders is anticipated to drive the expansion of the huntington’s disease market in the forthcoming period. Neurological disorders are medical conditions that impact the brain, spinal cord, and nerves, leading to symptoms such as impairments in movement, coordination, sensation, or cognition. The surge in neurological disorders can be attributed to factors like aging demographics, environmental toxins, alterations in lifestyle, enhanced diagnostic capabilities, and genetic predispositions, all of which aid in detecting and identifying more cases. Huntington’s disease is a neurodegenerative condition resulting from a genetic mutation, manifesting in motor dysfunction, cognitive decline, and psychiatric symptoms that progressively worsen over time. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported an estimated 6.7 million Americans aged 65 and older currently live with Alzheimer’s dementia. Without significant medical breakthroughs to prevent, slow, or cure the disease, this number is projected to increase to 13.8 million by 2060. Thus, the escalating prevalence of neurological disorders is propelling the growth of the huntington’s disease market.

How Is The Huntington’s Disease Market Organized Into Various Segments?

The huntington’s disease market covered in this report is segmented –

1) By Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, Other Treatment Types

2) By Diagnosis: Magnetic Resonance Imaging (MRI), Genetic Testing

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Symptomatic Therapy: Antipsychotics, Antidepressants, Mood Stabilizers, Muscle Relaxants

2) By Disease-Modifying Therapy: Gene Silencing Therapies, Neuroprotective Agents

3) By Other Treatment Types: Physical Therapy, Occupational Therapy, Speech Therapy

What Trends Are Projected To Support The Growth Of The Huntington’s Disease Market?

Leading companies in the huntington’s disease market are focusing on the development of novel solutions, such as oral small molecule drugs, to manage symptoms and slow the progression of the disease. An oral small molecule drug is a low-molecular-weight compound that can be taken by mouth and is formulated to engage with biological targets, including proteins or enzymes, for therapeutic purposes. For instance, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, secured Fast Track designation from the U.S. Food and Drug Administration (USFDA) for its PTC518 program, which targets Huntington’s disease treatment. This designation is granted to therapies that address significant unmet medical needs, highlighting the potential of PTC518 as a disease-modifying treatment for individuals suffering from this genetic disorder.

Who Are The Primary Competitors In The Global Huntington’s Disease Market?

Major companies operating in the huntington’s disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-global-market-report

Which Regions Are Poised For Strategic Growth In The Huntington’s Disease Market?

North America was the largest region in the huntington’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Huntington’s Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22008&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Market 2026, By The Business Research Company

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Progressive Ataxia And Weakness Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795